$585 Million is the total value of Casdin Capital, LLC's 31 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 30.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LOXO | LOXO ONCOLOGY INC | $50,425,000 | -18.0% | 360,000 | 0.0% | 8.63% | +15.4% | |
| MYOK | Sell | MYOKARDIA INC | $38,599,000 | -26.5% | 790,000 | -1.9% | 6.60% | +3.5% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $34,502,000 | -41.1% | 640,000 | -14.7% | 5.90% | -17.0% |
| CDXS | CODEXIS INC | $33,818,000 | -2.6% | 2,025,000 | 0.0% | 5.79% | +37.1% | |
| ONCE | Buy | SPARK THERAPEUTICS INC | $32,878,000 | -10.7% | 840,000 | +24.4% | 5.62% | +25.7% |
| BLUE | Buy | BLUEBIRD BIO INC | $32,736,000 | -13.1% | 330,000 | +27.9% | 5.60% | +22.3% |
| FATE | FATE THERAPEUTICS INC | $32,717,000 | -21.2% | 2,550,000 | 0.0% | 5.60% | +10.9% | |
| SAGE | SAGE THERAPEUTICS INC | $29,886,000 | -32.2% | 312,000 | 0.0% | 5.11% | -4.5% | |
| BLFS | BIOLIFE SOLUTIONS INC | $29,216,000 | -31.3% | 2,428,571 | 0.0% | 5.00% | -3.3% | |
| NVTA | INVITAE CORP | $26,544,000 | -33.9% | 2,400,000 | 0.0% | 4.54% | -6.9% | |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $25,883,000 | +9.5% | 355,000 | +31.5% | 4.43% | +54.2% |
| AGIO | Sell | AGIOS PHARMACEUTICALS INC | $20,519,000 | -54.1% | 445,000 | -23.2% | 3.51% | -35.4% |
| GNMK | Buy | GENMARK DIAGNOSTICS INC | $18,541,000 | -27.9% | 3,815,000 | +9.0% | 3.17% | +1.4% |
| BOLD | Buy | AUDENTES THERAPEUTICS INC | $18,335,000 | -25.9% | 860,000 | +37.6% | 3.14% | +4.3% |
| ILMN | Sell | ILLUMINA INC | $17,996,000 | -31.4% | 60,000 | -16.1% | 3.08% | -3.5% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $16,370,000 | +153.4% | 150,000 | +275.0% | 2.80% | +256.8% |
| MGTA | Buy | MAGENTA THERAPEUTICS INC | $15,067,000 | -44.3% | 2,643,317 | +17.4% | 2.58% | -21.5% |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $14,368,000 | -14.1% | 350,000 | -20.5% | 2.46% | +21.0% |
| SGMO | Sell | SANGAMO THERAPEUTICS INC | $12,398,000 | -63.4% | 1,080,000 | -46.0% | 2.12% | -48.5% |
| GRTS | GRITSTONE ONCOLOGY INC | $11,133,000 | +8.5% | 720,586 | 0.0% | 1.90% | +52.8% | |
| EVH | EVOLENT HEALTH INCcl a | $10,973,000 | -29.8% | 550,000 | 0.0% | 1.88% | -1.1% | |
| EDIT | Buy | EDITAS MEDICINE INC | $10,920,000 | -25.4% | 480,000 | +4.3% | 1.87% | +5.0% |
| VYGR | Sell | VOYAGER THERAPEUTICS INC | $10,604,000 | -50.6% | 1,128,075 | -0.6% | 1.81% | -30.5% |
| BGNE | BEIGENE LTDsponsored adr | $9,818,000 | -18.6% | 70,000 | 0.0% | 1.68% | +14.7% | |
| FIXX | HOMOLOGY MEDICINES INC | $7,826,000 | -2.2% | 350,000 | 0.0% | 1.34% | +37.8% | |
| CNST | Buy | CONSTELLATION PHARMCETICLS I | $6,244,000 | -29.4% | 1,556,998 | +18.4% | 1.07% | -0.7% |
| IBB | New | ISHARES TRnasdaq biotech | $5,786,000 | – | 60,000 | +100.0% | 0.99% | – |
| CDNA | CAREDX INC | $5,028,000 | -12.9% | 200,000 | 0.0% | 0.86% | +22.7% | |
| DNLI | New | DENALI THERAPEUTICS INC | $2,066,000 | – | 100,000 | +100.0% | 0.35% | – |
| QTNT | New | QUOTIENT LTD | $1,989,000 | – | 325,000 | +100.0% | 0.34% | – |
| NTGN | Sell | NEON THERAPEUTICS INC | $1,325,000 | -54.1% | 263,344 | -22.2% | 0.23% | -35.3% |
| JNCE | Exit | JOUNCE THERAPEUTICS INC | $0 | – | -375,000 | -100.0% | -0.30% | – |
| CTMX | Exit | CYTOMX THERAPEUTICS INC | $0 | – | -207,500 | -100.0% | -0.47% | – |
| GILD | Exit | GILEAD SCIENCES INCcall | $0 | – | -50,000 | -100.0% | -0.47% | – |
| CELG | Exit | CELGENE CORPcall | $0 | – | -50,000 | -100.0% | -0.54% | – |
| NEOG | Exit | NEOGEN CORP | $0 | – | -65,000 | -100.0% | -0.56% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INC | $0 | – | -235,000 | -100.0% | -0.84% | – |
| OSUR | Exit | ORASURE TECHNOLOGIES INC | $0 | – | -525,000 | -100.0% | -0.99% | – |
| CRSP | Exit | CRISPR THERAPEUTICS AGnamen akt | $0 | – | -220,000 | -100.0% | -1.19% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
| 13F-HR | 2024-02-14 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.